ECE2017 Eposter Presentations: Adrenal and Neuroendocrine Tumours Endocrine tumours and neoplasia (50 abstracts)
Survival analysis of patients with gastroenteropancreatic neuroendocrine tumors
Miguel Sampedro-Núñez 1, , Angeles Maillo-Nieto 1 , Ana María Ramos-Leví 1, , Isabel Huguet 1, , Sandra Campos 1, , Elena Fernandez 1 , Nerea Aguirre 1 , Jose Luis Muñoz de Nova 3 , Elena Martín 3 & Mónica Marazuela 1,
1Department of Endocrinology, Hospital Universitario de La Princesa, Madrid, Spain; 2Instituto de Investigación Princesa, Madrid, Spain; 3Department of Surgery, Hospital Universitario de La Princesa, Madrid, Spain.
Introduction: One of the main difficulties in the study of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) is their wide heterogeneity and variable outcome. Several potential influencing factors on patient survival have been recently identified. These factors could help predict patients’ prognosis.
Objectives: Analysis of long-term survival of our GEP-NETs cohort according to the presence of metastatic disease, tumor grade, age, sex, tumor functionality and tumor origin.
Materials and methods: Ambispective study of patients with GEP-NETs in Hospital Universitario La Princesa (Madrid, Spain) from 1995 to the present. Survival analysis and factors involved were assessed by Kaplan-Meier method and Cox regression analysis using STATA v12.0.
Results: One hundred and four patients were evaluated (55 women, age 61±16 years). Primary origin was pancreatic in 39, intestinal in 69 and unknown in 6 cases. Histological tumor grade was G1 in 51%, G2 in 39% and G3 in 10% of cases. 68% patients had metastatic disease and 33 died during follow-up. Median survival time was 5261 days (CI 3247 to not reached). Grade G3 multiplied the risk of mortality by 26 (CI 6 – 112); metastatic disease doubled the risk (CI 1.3 – 5.1); every 10-year increase in age multiplied the risk by 1.6 (CI 1.2 – 2.2); and if the tumor had unknown primary origin, the risk was multiplied by 2.5 (IC 0.9 – 7.4). Sex and tumor functionality did not significantly affect survival.
Conclusions: Several factors influence the heterogeneity and clinical outcome of patients with NETs. Median survival is reduced in patients with G3, metastasis, and primary tumors of unknown origin. Knowing these factors guides the therapeutic approach of this rare disease.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more